[Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003295
German
Original Title: Axitinib (Nierenzellkarzinom)
Details
Project Status: Completed
Year Published: 2017
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Axitinib
Keywords
  • Axitinib
  • Carcinoma - Renal Cell
  • Benefit Assessment
  • NCT00678392
  • NCT00920816
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.